<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449032</url>
  </required_header>
  <id_info>
    <org_study_id>MyStromalCell</org_study_id>
    <nct_id>NCT01449032</nct_id>
  </id_info>
  <brief_title>MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)</brief_title>
  <acronym>MyStromalCell</acronym>
  <official_title>MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery disease (CAD) is the most common cause of death and a major cause of hospital
      admissions for acute chest pain. In spite of improved treatments still many patients with CAD
      have daily attacks of severe chest pain and severely reduced life quality.

      The investigators have established a double-blind placebo-controlled trial in patients with
      CAD to test efficacy and safety of treatment with adipose derived stem cells to improve
      perfusion in the heart muscle and exercise capacity, and reduce the patient's symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an open single centre pilot study we have evaluated the safety and efficacy of MSC
      treatment to improve heart muscle perfusion in patients with chronic CAD. Patients treated
      with MSCs had significant increased exercise capacity, reduction in angina, angina attacks
      and medication and in life quality at 6 months follow-up. For all the parameters there was a
      tendency towards improved outcome with increasing number of cells. The treatment with MSCs
      was safe.

      The investigators have now established a double-blind placebo-controlled trial in patients
      with CAD to test efficacy and safety of treatment with MSCs to improve perfusion in the heart
      muscle and exercise capacity, and reduce the patient's symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise test</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>MSC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adipose derived stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC</intervention_name>
    <description>No of cells after culture expansion</description>
    <arm_group_label>MSC</arm_group_label>
    <other_name>Adipose derived stem cells</other_name>
    <other_name>Mesenchymal stromal cells</other_name>
    <other_name>Mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>3 cc saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CCS III - IV

          -  Coronary artery stenosis/occlusion not treatable with invasive procedures

          -  LVEF &gt; 40%

          -  ETT between 2 - 10 min

        Exclusion Criteria:

          -  Valvular heart disease

          -  FEV1 &lt; 1

          -  Severe systemic disease

          -  Acute coronary syndrome &gt; 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Kastrup, MD Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>210</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>June 7, 2014</last_update_submitted>
  <last_update_submitted_qc>June 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>JKastrup</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

